Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStoptm for the treatment of acid reflux, a treatment field ...
Daiichi Sankyo Company, , an innovative global healthcare company, has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as chief executive officer (CEO), effective April 1, 2025. Dr ...
Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in oncology, driven by ENHERTU’s market leadership and robust sales growth across regions. Despite regulatory delays for Datroway ...
Japanese drugmaker Daiichi Sankyo (TYO: 4568) has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025. Dr Manabe will transition from his current role ...
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1.
The DOJ has told legal service providers to stop providing immigration help. A group of immigrant advocacy centers and nonprofits has filed a lawsuit against the Department of Justice and the ...
Two oncology treatments also received CHMP’s blessing. AstraZeneca and Daiichii Sankyo’s antibody-drug conjugate (ADC) Datroway was recommended for certain patients with unresectable or ...
(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...
TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...
Thank you very much for waiting. We will now would like to start Daiichi Sankyo's Financial Results Briefing for the Third Quarter of Fiscal Year 2024. My name is Asakura from Corporate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback